EUVIMEDEUVIMED entdecken
Open Access

Standards for clinical trials for treating TB

P du Cros, J Greig, J-W C Alffenaar, G B Cross, C Cousins, C Berry, U Khan, P P J Phillips, G E Velásquez, J Furin, M Spigelman, J T Denholm und 28 weitere

The International Journal of Tuberculosis and Lung Disease · 01.12.2023 · 27 (12) · 885-898

DOI: 10.5588/ijtld.23.0341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 01.12.2023. Verfasst von P du Cros und 39 weiteren Autor:innen. Beteiligte Einrichtung: Burnet Institute, Melbourne, VIC, Monash Infectious Diseases, Monash Health, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Tuberculosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice. METHODS: A global panel of experts participated in a Delphi process, using a 7-point Likert scale to score and revise draft standards until consensus was reached. RESULTS: Eleven standards were defined: Standard 1, high quality data on TB regimens are essential to inform clinical and programmatic management; Standard 2, the research questions addressed by TB trials should be relevant to affected communities, who should be included in all trial stages; Standard 3, trials should make every effort to be as inclusive as possible; Standard 4, the most efficient trial designs should be considered to improve the evidence base as quickly and cost effectively as possible, without compromising quality; Standard 5, trial governance should be in line with accepted good clinical practice; Standard 6, trials should investigate and report strategies that promote optimal engagement in care; Standard 7, where possible, TB trials should include pharmacokinetic and pharmacodynamic components; Standard 8, outcomes should include frequency of disease recurrence and post-treatment sequelae; Standard 9, TB trials should aim to harmonise key outcomes and data structures across studies; Standard 10, TB trials should include biobanking; Standard 11, treatment trials should invest in capacity strengthening of local trial and TB programme staff. CONCLUSION: These standards should improve the efficiency and effectiveness of evidence generation, as well as the translation of research into policy and practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisHumansBiological Specimen BanksClinical Trials as Topic

Autor:innen und Institutionen

  • Burnet Institute, Melbourne, VIC, Monash Infectious Diseases, Monash Health, Melbourne, VIC, Australia.
  • Burnet Institute, Melbourne, VIC, Médecins Sans Frontières (MSF), Manson Unit, London, UK.
  • Sydney Infectious Diseases Institute (Sydney ID), and, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Westmead Hospital, Sydney, NSW.
  • Burnet Institute, Melbourne, VIC, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Médecins Sans Frontières (MSF), Manson Unit, London, UK.

Förderung

  • NIAID NIH HHS

Zitieren

APA

du Cros, P., Greig, J., Alffenaar, J. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., …, & Marais, B. J. (2023). Standards for clinical trials for treating TB. The International Journal of Tuberculosis and Lung Disease, 27(12), 885-898. https://doi.org/10.5588/ijtld.23.0341

Vancouver

du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, et al. Standards for clinical trials for treating TB. The International Journal of Tuberculosis and Lung Disease. 2023;27(12):885-898. doi:10.5588/ijtld.23.0341

BibTeX
@article{duCros2023,
  author = {du Cros, P and Greig, J and Alffenaar, J-W C and Cross, G B and Cousins, C and Berry, C and Khan, U and Phillips, P P J and Velásquez, G E and Furin, J and Spigelman, M and Denholm, J T and Thi, S S and Tiberi, S and Huang, G K L and Marks, G B and Turkova, A and Guglielmetti, L and Chew, K L and Nguyen, H T and Ong, C W M and Brigden, G and Singh, K P and Motta, I and Lange, C and Seddon, J A and Nyang'wa, B-T and Maug, A K J and Gler, M T and Dooley, K E and Quelapio, M and Tsogt, B and Menzies, D and Cox, V and Upton, C M and Skrahina, A and McKenna, L and Horsburgh, C R and Dheda, K and Marais, B J},
  title = {Standards for clinical trials for treating TB},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2023},
  volume = {27},
  number = {12},
  pages = {885--898},
  doi = {10.5588/ijtld.23.0341}
}
Kostenlos starten →